Amgen to Invest $300 Million in New Biomanufacturing Facility
Pharmaceutical Technology Magazine | February 06, 2018
The new manufacturing facility will employ Amgen's next-generation biomanufacturing capabilities and will be used to manufacture products for the US and export markets. According to the company, next-generation biomanufacturing requires less time and less capital investment to build than a traditional biomanufacturing plant. It is also less costly to operate and has less of an environmental impact, states the company.